Literature DB >> 19116843

Can subdural hematoma be a trigger for Guillain-Barré syndrome?

Nilgul Yardimci1, Salih Gulsen, Aynur Yilmaz Avci, Nur Altinors, Turgut Zileli, Ufuk Can.   

Abstract

Guillain-Barré syndrome (GBS) is an acute inflammatory polyneuropathy which follows a precipitating event in approximately two thirds of cases. Although its pathogenesis is unclear, it is likely to be a consequence of an immune-mediated process. In the literature there are three case reports of GBS following subarachnoid hemorrhage, subdural hematoma, and facial bone fracture after head trauma.The unique feature of our case with GBS after subdural hematoma is the presence of cerebellar symptoms. We believe that GBS results from an aberrant immune response following trauma that somehow mistakenly attacks the nerve tissue of its host, and we discuss the effects of the trauma of head injury on cellular and humoral immunities and the absence of antiganglioside antibody (anti-GD1b IgG, which is accused of ataxia and cerebellar symptoms) in this case report.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19116843     DOI: 10.1080/00207450802480135

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  3 in total

1.  Guillain-barre syndrome following spinal fusion for thoracic vertebral fracture.

Authors:  Dong Wuk Son; Geun Sung Song; Sun Ki Sung; Sung Hoon Kim
Journal:  J Korean Neurosurg Soc       Date:  2011-11-30

Review 2.  Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review.

Authors:  Kenichi Kaida; Toshio Ariga; Robert K Yu
Journal:  Glycobiology       Date:  2009-02-24       Impact factor: 4.313

3.  Fulminant Guillain-Barré Syndrome and Spontaneous Intraventricular Hemorrhage: A Case Report and Literature Review.

Authors:  Jun Hu; Xiaoqian Luo; Yu Wang; Eric Prado; Qinghui Fu; Anwen Shao
Journal:  Front Neurosci       Date:  2020-06-30       Impact factor: 4.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.